[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ascendis Pharma ADR (ASND)

Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,886,892
  • Shares Outstanding, K 62,377
  • Annual Sales, $ 814,760 K
  • Annual Income, $ -258,000 K
  • EBIT $ -154 M
  • EBITDA $ -134 M
  • 60-Month Beta 0.41
  • Price/Sales 18.85
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 36.12% (-2.82%)
  • Historical Volatility 44.29%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 70.31% on 08/01/25
  • IV Low 36.12% on 05/08/26
  • Expected Move (DTE 5) 19.42 (8.14%)
  • Put/Call Vol Ratio 0.81
  • Today's Volume 428
  • Volume Avg (30-Day) 817
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 10,960
  • Open Int (30-Day) 13,527
  • Expected Range 219.24 to 258.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.77
  • Number of Estimates 8
  • High Estimate $1.45
  • Low Estimate $0.08
  • Prior Year $-0.93
  • Growth Rate Est. (year over year) +182.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
216.22 +10.38%
on 04/29/26
250.74 -4.82%
on 04/13/26
+5.46 (+2.34%)
since 04/08/26
3-Month
211.00 +13.11%
on 02/12/26
250.74 -4.82%
on 04/13/26
+16.51 (+7.43%)
since 02/06/26
52-Week
150.89 +58.17%
on 05/15/25
250.74 -4.82%
on 04/13/26
+79.27 (+49.73%)
since 05/08/25

Most Recent Stories

More News
Ascendis Pharma A/S Q1 Earnings Call Highlights

Ascendis Pharma A/S (NASDAQ:ASND) reported first-quarter 2026 results highlighted by the U.S. FDA approval of its third TransCon product, YUVIWEL, and continued growth across its rare endocrine portfolio....

ASND : 238.66 (-3.04%)
Ascendis Pharma Reports First Quarter 2026 Financial Results

- Q1 2026 revenue of €197 million for YORVIPATH ®   and €44 million for SKYTROFA ® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than...

ASND : 238.66 (-3.04%)
Ascendis Pharma's First Profitable Quarter May Finally Be Within Reach

Barchart Research What to Expect from ASND Earnings ASND Generated May 6, 2026 Current Price $235.90 EPS Estimate $$0.21 Consensus Rating Strong Buy Average Move 4.66% Ascendis Pharma's First Profitable...

ASND : 238.66 (-3.04%)
New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years

COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from a subgroup analysis showing that children with achondroplasia ≥5 years of age...

ASND : 238.66 (-3.04%)
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026

COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report first quarter 2026 financial results and provide a business update on Thursday,...

ASND : 238.66 (-3.04%)
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028

COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Convertible...

ASND : 238.66 (-3.04%)
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq

COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq),...

ASND : 238.66 (-3.04%)
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

 - Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs)  - ADS holders will receive one ordinary share listed on Nasdaq...

ASND : 238.66 (-3.04%)
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia

- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination therapy, a measure highly meaningful to the achondroplasia community - Enhanced improvements in spinal...

ASND : 238.66 (-3.04%)
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

- YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses - YUVIWEL is now commercially...

ASND : 238.66 (-3.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,...

See More

Key Turning Points

3rd Resistance Point 261.26
2nd Resistance Point 255.77
1st Resistance Point 247.21
Last Price 238.66
1st Support Level 233.16
2nd Support Level 227.67
3rd Support Level 219.11

See More

52-Week High 250.74
Last Price 238.66
Fibonacci 61.8% 212.60
Fibonacci 50% 200.82
Fibonacci 38.2% 189.03
52-Week Low 150.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.